Sourced from ClinicalTrials.gov · field-grounded rewrites · not medical advice
We do not write medical opinions. We take the official ClinicalTrials.gov record, keep the NCT number on the page, and rewrite only what the registry already says.
ClinicalTrials.gov API v2. NCT, sponsor, sites, eligibility — stored unchanged.
Rules parse inclusion/exclusion first. Llama, if on, runs at temperature 0 and is discarded if it adds a fact.
Every card links to the official record. The JSON dataset is public. Sitemap lastmod follows ingest.
A step-by-step way to search recruiting studies on ClinicalTrials.gov and PlainTrials, then confirm eligibility with the study team. Not medical advice.
What NCT, Overall Status, Phase, Eligibility, and Contacts mean on an official ClinicalTrials.gov study record. Not medical advice.
What inclusion and exclusion criteria are, why trials use them, and how to read them on ClinicalTrials.gov. Not a determination of whether you qualify.
What informed consent is supposed to cover, that you can leave a study, and that a website rewrite is not a consent form.
What placebo, double-blind, and randomized mean on a ClinicalTrials.gov record, in plain English. Not medical advice.
What to ask about study-paid tests, insurance, stipends, and visit burden. Practices vary by sponsor and site. Not financial or medical advice.
Trials testing new drugs, antibody therapies, surgery timing, and radiation approaches.
Hormone therapy, PSMA-targeted drugs, and active-surveillance studies.
Immunotherapy, targeted pills for EGFR/ALK, and early-detection studies.
Immunotherapy, targeted drugs, and surgery-timing studies for colon and rectal cancer.
Chemotherapy combinations, KRAS-targeted drugs, and earlier-detection studies.
Checkpoint drugs, TIL therapy, and adjuvant studies after surgery.
PARP inhibitors, antibody-drug conjugates, and maintenance after platinum therapy.
Surgery, radiation, temozolomide combinations, and experimental brain-tumor drugs.
Targeted pills, antibodies, CAR-T, and transplant-related studies for blood cancers.
CAR-T, bispecific antibodies, and chemotherapy-sparing studies for Hodgkin and NHL.
Bispecifics, CAR-T, and maintenance studies after transplant or relapsed disease.
Immunotherapy, VEGF drugs, and adjuvant studies after kidney surgery.
BCG, immunotherapy, antibody-drug conjugates, and bladder-sparing approaches.
Immunotherapy, TACE combinations, and transplant-window studies for HCC.
HER2, Claudin 18.2, immunotherapy, and perioperative chemotherapy studies.
Immunotherapy, HPV-related studies, and treatments for recurrent disease.
Immunotherapy, targeted drugs, and studies after surgery or at recurrence.
HPV-related oropharynx studies, immunotherapy, and radiation combinations.
Amyloid and tau drugs, lifestyle trials, and studies for caregivers and prevention.
Dopamine therapies, device implants, and trials aimed at slowing progression.
B-cell drugs, remyelination experiments, and progressive-MS trials.
CGRP blockers, devices, and prevention vs. rescue studies.
Drug, gene, and device studies for amyotrophic lateral sclerosis.
Add-on medicines, devices, and surgery-related studies for seizures.
Recovery, prevention after a first stroke, and acute hospital studies.
GLP-1 and SGLT2 drugs, insulin combinations, and diet or device studies.
Weight-loss medicines (including GLP-1s), surgery, and behavioral programs.
MASH/NASH drug trials, fibrosis imaging studies, and metabolic combinations.
SGLT2 drugs, anemia treatments, and dialysis-sparing studies.
Metabolic, fertility, and symptom studies for polycystic ovary syndrome.
Fast-acting medicines, psychedelics, TMS, and add-on treatments after an antidepressant.
Therapy plus medicine studies, including some psychedelic-assisted protocols.
Maintenance, depression, and mania studies with medicines or therapy.
Antipsychotic, negative-symptom, and cognition studies.
GAD and related anxiety studies with medicines, therapy, or digital tools.
Medicine, digital, and adult-ADHD studies from the public registry.
Biologics, JAK inhibitors, and tapering studies for people already on treatment.
B-cell and interferon-pathway drugs for SLE and lupus nephritis.
Injectable biologics, oral TYK2 drugs, and combination skin studies.
Gut-targeted biologics, oral drugs, and diet studies.
Gut-targeted biologics, oral small molecules, and combination induction studies.
Knee and hip pain studies, injections, devices, and exercise programs.
Biologics, JAK inhibitors, and topical studies for eczema.
Diet, microbiome, and medicine studies for irritable bowel syndrome.
SGLT2 drugs, devices, and rehab programs for reduced or preserved ejection fraction.
Ablation, anticoagulants, and rhythm-control studies for AFib.
Medicine, device, and lifestyle studies for high blood pressure.
Biologics, inhaler combinations, and studies for severe or eosinophilic asthma.
Inhalers, biologics, and rehab studies for chronic obstructive pulmonary disease.
Devices, GLP-1 medicines, and surgery alternatives to CPAP.
A GLP-1 weekly shot (and a daily pill) being tested far beyond diabetes — obesity, heart, kidney, liver, and addiction studies.
A dual GIP/GLP-1 weekly shot. Trials now cover weight, sleep apnea, heart failure, and fatty liver.
An investigational triple-agonist studied for obesity and metabolic disease.
A PD-1 immunotherapy used across many cancers. New trials test earlier use, combinations, and shorter courses.
A PD-1 immunotherapy studied alone and with ipilimumab or chemotherapy.
An HER2-directed antibody-drug conjugate studied in breast, lung, gastric, and other tumors.
An EGFR tyrosine-kinase inhibitor studied in lung cancer and related settings.
A KRAS G12C inhibitor studied in lung cancer and other G12C tumors.
An anti-amyloid antibody for early Alzheimer's. Trials look at prevention, dosing, and who is most likely to benefit.
Another anti-amyloid Alzheimer's antibody. Studies compare it with similar drugs and test stopping rules.
Rapid-acting depression treatment. Trials test dose, route (IV vs. nasal), and how to keep the effect from fading.
A psychedelic being studied for depression, addiction, and end-of-life distress — always with therapy, not as a take-home pill.
A patient's own immune cells are reprogrammed to attack cancer. Trials are expanding from blood cancers into solid tumors and autoimmune disease.
An IL-4/IL-13 antibody studied in asthma, eczema, eosinophilic diseases, and COPD-overlap trials.
A B-cell antibody used in multiple sclerosis. Trials test earlier use, dosing, and progressive disease.
A B-cell therapy studied in multiple sclerosis and, in other records, hematologic disease.
An SGLT2 inhibitor studied in diabetes, heart failure, and kidney disease.
An SGLT2 inhibitor with heart-failure, CKD, and diabetes studies on the registry.
A TNF blocker studied across inflammatory diseases, including biosimilar protocols.
An IL-23 antibody studied in psoriasis, psoriatic arthritis, and IBD.
A TSLP antibody studied in severe asthma and related airway disease.
A bispecific eye injection studied in wet AMD and diabetic macular edema.
A long-acting HIV capsid inhibitor studied in treatment and prevention records.
A CDK4/6 inhibitor studied mainly in hormone-receptor-positive breast cancer.
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.
NCT03414502 · Official ClinicalTrials.gov record · University of Nebraska
This study wants to measure the long-term safety and how well it works of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase.
NCT03486873 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
This multicenter, open-label, randomly assigned phase 3 trial will determine if palbociclib and cetuximab (Arm 1) improves overall survival (OS) in comparison to cetuximab this drug alone (Arm 2) in patients with CDKN2A-altered, HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on a PD-1/L1 inhibitor (given as this drug alone or in combination with other therapy).
NCT04966481 · Official ClinicalTrials.gov record · Washington University School of Medicine
The main objective of the study is to assess how well it works and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, neither you nor the study doctors know who gets the real treatment, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO.
NCT05263206 · Official ClinicalTrials.gov record · Sanofi
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active dummy treatment (placebo) (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.
NCT05398484 · Official ClinicalTrials.gov record · NYU Langone Health
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy.
NCT05677490 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
The goal of this clinical trial is to assess the how well it works, whether it is safe and how hard side effects are to live with of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the how well it works of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
NCT05696626 · Official ClinicalTrials.gov record · LeonaBio
The goal of this randomly assigned clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the % of patients without disease activity at 2 years.
NCT05758831 · Official ClinicalTrials.gov record · Rennes University Hospital
Studies that list a site in California on ClinicalTrials.gov.
Studies that list a site in Texas on ClinicalTrials.gov.
Studies that list a site in Florida on ClinicalTrials.gov.
Studies that list a site in New York on ClinicalTrials.gov.
Studies that list a site in Maryland on ClinicalTrials.gov.
Studies that list a site in Ohio on ClinicalTrials.gov.
Studies that list a site in Pennsylvania on ClinicalTrials.gov.
Studies that list a site in Illinois on ClinicalTrials.gov.
Studies that list a site in North Carolina on ClinicalTrials.gov.
Studies that list a site in Georgia on ClinicalTrials.gov.
Studies that list a site in Michigan on ClinicalTrials.gov.
Studies that list a site in Massachusetts on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
Studies that list a site here on ClinicalTrials.gov.
No. Listings are plain-English rewrites of public ClinicalTrials.gov records. They are not a diagnosis, a referral, or a recommendation to join a study. Confirm eligibility with the study team and your clinician.
ClinicalTrials.gov API v2. Each trial page keeps the NCT identifier and a hyperlink to the official record. If a rewrite disagrees with the registry, the registry wins.
The sponsor posted Overall Status = Recruiting on ClinicalTrials.gov at the time we ingested the record. It is not a live waitlist for every hospital site.
No. Inclusion and exclusion criteria are summarized from the public eligibility block. Only the study team can screen you (labs, imaging, consent).
No. PlainTrials is an open-data rewriting project. We are not a hospital, CRO, sponsor, or IRB.
A scheduled job re-pulls recruiting studies from the live API and regenerates sitemap.xml. Each page shows the ingest timestamp. lastmod in the sitemap follows that ingest.